Kisqali is an oral cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitor. CDK 4/6 are commonly overexpressed in breast cancer tumors, and increased CDK 4/6 activity is associated with resistance to hormone therapy. Kisqali is intended for use in combination with letrozole (brand name Femara; Novartis), an aromatase inhibitor commonly prescribed for first-line hormone therapy in women with HR+/HER2– breast cancer.
If you have a Hayes login, click here to view the full report on the Knowledge Center.